FDA Neurological Devices Panel
This article was originally published in The Gray Sheet
Cancels scheduled Jan. 28 meeting. Analysts note that the panel was expected to review Medtronic's Activa neurostimulation device for Parkinson's treatment (1"The Gray Sheet" Nov. 29, p. 15). Quarterly panel meetings in 2000 are tentatively scheduled on May 11-12, Aug. 17-18, and Nov. 16-17
You may also be interested in...
Medtronic's Synergy dual-channel neurostimulation system for chronic intractable pain of the trunk and limbs is expected to account for roughly 25% of the company's neurostimulation business following its U.S. rollout Nov. 22, Medtronic says.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.